Literature DB >> 14531625

The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia.

F Bottoni1, M Tilanus.   

Abstract

BACKGROUND: To assess the natural history of juxtafoveal and subfoveal choroidal neovascularization in eyes with high myopia.
METHODS: We retrospectively reviewed the charts of 31 patients (31 eyes) with myopia > or = 6 diopters, well-defined juxtafoveal (1-200 microm from the foveal center) or subfoveal choroidal neovascularization (CNV) on fluorescein angiography at baseline, no prior laser treatment, age < or = 55 years and presenting visual acuity (VA) > or = 20/200. Initial and final VA were compared with the Wilcoxon signed rank test. Multifactor analysis of variance was used to assess the association between baseline characteristics of the lesion and final VA.
RESULTS: Twenty-two patients were females and 9 males with a median age of 44 years (range 14-55). Median diopters spherical equivalent was -11.5 (range -6, -25). Follow-up ranged from 1 to 20 years (median, 3 years). Nine eyes had juxtafoveal CNV and 22 subfoveal involvement. Median final VA (20/100) was significantly worse than median initial VA (20/50)(p = 0.02). A decrease in VA > or = 2 lines occurred in 18 eyes, whereas 8 eyes remained stable and 5 improved (4 juxtafoveal membranes and 1 subfoveal membrane). Of the 9 juxtafoveal CNV, 7 had a final VA > or = 20/40 after a median follow-up of 4 years. By contrast, only 2 of the 22 subfoveal CNV had a final VA > or = 20/40 (median, 20/100) with a median follow-up of 2.5 years. The only factor associated with better final VA was the initial location of CNV (p = 0.0000).
CONCLUSION: This study confirms the poor functional outcome of subfoveal CNV in degenerative myopia with more than 70% of patients having a final VA of 20/100 or less. Juxtafoveal CNV shows a better functional prognosis. These differences should be considered when planning treatment strategies.

Entities:  

Mesh:

Year:  2001        PMID: 14531625     DOI: 10.1023/a:1025488429802

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  14 in total

1.  Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors: 
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

2.  Axial length measurements and fundus changes of the myopic eye.

Authors:  B J Curtin; D B Karlin
Journal:  Am J Ophthalmol       Date:  1971-01       Impact factor: 5.258

3.  Pathologic myopia and choroidal neovascularization.

Authors:  M L Hotchkiss; S L Fine
Journal:  Am J Ophthalmol       Date:  1981-02       Impact factor: 5.258

4.  Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization.

Authors:  H Tabandeh; H W Flynn; I U Scott; M L Lewis; P J Rosenfeld; F Rodriguez; A Rodriguez; L J Singerman; J Schiffman
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

5.  Etiology of choroidal neovascularization in young patients.

Authors:  S Y Cohen; A Laroche; Y Leguen; G Soubrane; G J Coscas
Journal:  Ophthalmology       Date:  1996-08       Impact factor: 12.079

6.  Surgical removal of subfoveal choroidal neovascular membranes in high myopia.

Authors:  F Bottoni; E Perego; P Airaghi; M Cigada; S Ortolina; G Carlevaro; V De Molfetta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-07       Impact factor: 3.117

7.  Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups.

Authors:  Takeshi Yoshida; Kyoko Ohno-Matsui; Yoshiteru Ohtake; Takayuki Takashima; Soh Futagami; Takayuki Baba; Kenjiro Yasuzumi; Takashi Tokoro; Manabu Mochizuki
Journal:  Ophthalmology       Date:  2002-04       Impact factor: 12.079

8.  Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment.

Authors:  M Secrétan; D Kuhn; G Soubrane; G Coscas
Journal:  Eur J Ophthalmol       Date:  1997 Oct-Dec       Impact factor: 1.922

9.  Natural history of choroidal neovascularization in degenerative myopia.

Authors:  M P Avila; J J Weiter; A E Jalkh; C L Trempe; R C Pruett; C L Schepens
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

10.  Visual prognosis of disciform degeneration in myopia.

Authors:  G R Hampton; D Kohen; A C Bird
Journal:  Ophthalmology       Date:  1983-08       Impact factor: 12.079

View more
  11 in total

Review 1.  Choroidal neovascularisation in pathological myopia: an update in management.

Authors:  W-M Chan; M Ohji; T Y Y Lai; D T L Liu; Y Tano; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.

Authors:  João Coelho; André Ferreira; Ana Carolina Abreu; Sílvia Monteiro; Maria João Furtado; Miguel Gomes; Miguel Lume
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-21       Impact factor: 3.117

3.  Choroidal neovascularization in 36 eyes of children and adolescents.

Authors:  P Rishi; A Gupta; E Rishi; B J Shah
Journal:  Eye (Lond)       Date:  2013-07-26       Impact factor: 3.775

4.  Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  H Nakanishi; A Tsujikawa; Y Yodoi; Y Ojima; A Otani; H Tamura; K Yamashiro; S Ooto; N Yoshimura
Journal:  Eye (Lond)       Date:  2011-01-21       Impact factor: 3.775

5.  The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization.

Authors:  Buğra Karasu; Ali Rıza Cenk Celebi
Journal:  Int Ophthalmol       Date:  2022-03-31       Impact factor: 2.029

6.  Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration.

Authors:  Masoud Salehipour; Nasser Vafi; Azade Doozande; Mehdi Yaseri
Journal:  J Ophthalmic Vis Res       Date:  2010-01

7.  Choroidal neovascularization in patient undergoing growth hormone treatment.

Authors:  João R de Oliveira Dias; Eduardo B Rodrigues; Maurício Martinazzo; Michel E Farah
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 8.  Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.

Authors:  Yan Zhang; Qian Han; Yusha Ru; Qiyu Bo; Rui Hua Wei
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

9.  Angiofluorographic Characteristics of Choroidal Neovascularization associated with Pathologic Myopia.

Authors:  Anca Tomi; Irina Ştefan
Journal:  Rom J Ophthalmol       Date:  2020 Oct-Dec

10.  Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.

Authors:  Jia-Kang Wang; Tzu-Lun Huang; Pei-Yao Chang; Yen-Ting Chen; Chin-Wei Chang; Fang-Ting Chen; Yung-Ray Hsu; Yun-Ju Chen
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.